OKYO Pharma Limited (OKYO) Key Metrics
OKYO valuation today
Trailing 12 months · as of October 17, 2026- Market cap
- $74.0M
- Enterprise value
- $64.2M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- —
- Price / book
- 5.5
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- −0.06
OKYO key metrics, FY2024–FY2026
Fiscal year ended March 31, 2026 · U.S. dollarsOKYO valuation Price multiples at each fiscal year-end price.
OKYO returns How much profit the business earns on the capital it uses.
OKYO per-share figures Results divided by the shares outstanding at year-end.
OKYO financial health Debt, liquidity and how easily interest is covered.
OKYO efficiency & capital use Working capital cycle and where the cash goes.
OKYO valuation history
OKYO returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
OKYO debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
OKYO price vs earnings per share
OKYO key metrics
FY2024–FY2026| FY2026 | FY2025 | FY2024 | |
|---|---|---|---|
| Valuation | |||
| Market capitalization | $60.1M | $50.2M | $43.7M |
| Enterprise value | $39.6M | $48.6M | $42.9M |
| Price / book | 4.9 | — | — |
| Earnings yield | −14.9% | −9.4% | −38.5% |
| Free cash flow yield | −9.9% | −3.6% | −21.7% |
| Share price at fiscal year-end | $1.61 | $1.27 | $1.49 |
| Per share | |||
| Revenue per share | $0.00 | $0.00 | $0.00 |
| Earnings per share | −$0.24 | −$0.12 | −$0.57 |
| Operating cash flow per share | −$0.16 | −$0.05 | −$0.32 |
| Free cash flow per share | −$0.16 | −$0.05 | −$0.32 |
| Cash per share | $0.55 | $0.04 | $0.03 |
| Book value per share | $0.33 | −$0.14 | −$0.20 |
| Tangible book value per share | $0.33 | −$0.14 | −$0.20 |
| Capex per share | $0.00 | $0.00 | $0.00 |
| Shares outstanding | 37.4M | 39.5M | 29.3M |
| Change in shares outstanding | −5.4% | +34.6% | — |
| Returns & profitability | |||
| Return on equity (ROE) | −263.8% | — | — |
| Return on assets (ROA) | −72.6% | −180.4% | — |
| Return on tangible assets | −42.7% | −128.0% | — |
| Financial health | |||
| Cash & short-term investments | $20.6M | $1.6M | $826,848 |
| Net debt | −$20.6M | −$1.6M | −$826,848 |
| Current ratio | 2.43 | 0.40 | 0.21 |
| Quick ratio | 2.43 | 0.40 | 0.21 |
| Interest coverage | -17.9 | -8.1 | -15.0 |
| Working capital | $12.3M | −$5.6M | −$5.9M |
| Invested capital | −$8.3M | −$7.1M | −$6.7M |
| Tangible asset value | $12.3M | −$5.5M | −$5.9M |
| Net current asset value | $12.3M | −$5.6M | −$5.9M |
| Graham net-net per share | $0.32 | −$0.16 | −$0.21 |
| Capital allocation | |||
| Capex / depreciation | 3.34 | 0.47 | 0.00 |
| Efficiency | |||
| Days payables outstanding | 410.1 | 998,880.8 | 298.0 |
| Receivables turnover | 0.00 | 0.00 | 0.00 |
| Payables turnover | 0.89 | 0.00 | 1.22 |
| Asset turnover | 0.00 | 0.00 | 0.00 |
| Average receivables | $1.0M | $1.2M | $580,940 |
| Average payables | $7.5M | $7.0M | $6.1M |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% |
Computed from OKYO's annual financial statements (latest annual report filed July 20, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
OKYO valuation and financial ratios
OKYO Pharma earned a return on equity of −263.8% in fiscal 2026.
See the OKYO income statement, the OKYO chart for price history, or the OKYO stock overview for the latest quote and news.
OKYO key metrics FAQ
What is OKYO Pharma's return on equity?
OKYO Pharma's return on equity (ROE) was −263.8% in fiscal 2026: net income of -$8.9 million on average shareholders' equity of $3.4 million.
What is OKYO Pharma's free cash flow yield?
OKYO Pharma generated -$5.9 million of free cash flow in fiscal 2026, a free cash flow yield of −9.9% on its market value at year-end ($60.1 million).
What is OKYO Pharma's current ratio?
OKYO Pharma's current ratio was 2.43 at the end of fiscal 2026: current assets were 2.43 times current liabilities.